Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – Intravenous magnesium sulfate infusions may not help patients with acute aneurysmal subarachnoid hemorrhage, according to a study published in the August issue of…
NEW YORK (Reuters Health) – The new-generation zotarolimus-eluting coronary stent was as safe and effective after 13 months’ follow-up as the everolimus-eluting stent in a study with minimal…
NEW YORK (Reuters Health) – By evaluating risk factors for thromboembolism, physicians can reduce the number of computed tomography (CT) angiograms they order for patients with suspected pulmonary…
NEW YORK (Reuters Health) – Enterally administered probiotic treatment with Lactobacillus rhamnosus GG can cut the rate of ventilator-associated pneumonia (VAP) in high-risk patients, according to pilot study…
NEW YORK (Reuters Health) – Nine times out of 10, patients admitted to a U.S. hospital for acute exacerbation of chronic obstructive pulmonary disease (COPD) are treated initially…
NEW YORK (Reuters Health) – Incidental findings on brain magnetic resonance imaging (MRI) scans are seen in a significant minority of children, although most of these findings are…
Program Survey Please click here to participate in our 15-second survey to provide feedback on this program. Program Overview As clinicians, we know that taking folic acid prior…
We wrap up our coverage with the week’s highlights from the AMA Annual Meeting of the House of Delegates in 4 minutes. Sponsored by the American Medical Association
NEW YORK (Reuters Health) – The novel antiarrhythmic agent vernakalant is a safe and effective agent for pharmacologic conversion of recent-onset atrial fibrillation (AF) in hemodynamically stable patients,…
NEW YORK (Reuters Health) – Nonintravenous midazolam (Versed) is better at ending status epilepticus than diazepam (Valium) in children and young adults, and is just as safe, according…
